Bioregulatory & Senescence Research Guide

FOX-04: Mechanism, Handling & Research Guide

Also known as: FOXO4-DRI, FOXO4 D-Retro-Inverso, FOXO4-DRI peptide, Proxofim, FOXO4-p53 interfering peptide, FOX-04, FOXO4 DRI

Key Facts

FOX-04 is a bioregulatory & senescence research peptide (C228H388N86O64, MW 5358.05 g/mol). Senolytic peptide for selective senescent cell clearance research. It is supplied as a lyophilized powder for laboratory and in-vitro research use only — not for human consumption.

Classification	FOXO4-p53 protein-protein interaction disruptor; D-retro-inverso peptide senolytic (research tool)
Molecular Formula	C228H388N86O64
Molecular Weight	5358.05 g/mol
Research Half-Life	Not well characterized; D-retro-inverso (all-D, reversed-sequence) design confers protease resistance versus the L-peptide, but no validated pharmacokinetic half-life is reported in humans (preclinical compound).
Form	Lyophilized powder
Research Category	Bioregulatory & Senescence

What is FOX-04?

FOXO4-DRI (Proxofim) is a D-retro-inverso peptide designed to disrupt the interaction between FOXO4 (Forkhead box O4) and p53 in senescent cells. In cellular senescence, FOXO4 sequesters p53 in the nucleus, preventing p53-mediated apoptosis and allowing damaged senescent cells to persist. FOXO4-DRI competitively binds FOXO4, displacing p53, which then translocates to mitochondria and triggers the intrinsic apoptotic pathway selectively in senescent cells, while leaving healthy cells unaffected due to their low FOXO4 expression. The landmark study by Baar et al. (2017) published in Cell demonstrated that FOXO4-DRI selectively induced apoptosis in senescent human fibroblasts in vitro and cleared senescent cells in naturally aged and fast-aging XpdTTD/TTD mice in vivo. Treated mice showed restored fur density, improved renal function, and increased exploratory behavior. This study established FOXO4-DRI as one of the first peptide-based senolytics with demonstrated in vivo efficacy. Follow-up research has explored its effects on senescence-associated secretory phenotype (SASP) reduction and tissue rejuvenation markers. Compared to small-molecule senolytics like dasatinib plus quercetin (D+Q) or navitoclax (ABT-263), FOXO4-DRI operates through a fundamentally different mechanism targeting the FOXO4-p53 protein-protein interaction rather than Bcl-2 family anti-apoptotic proteins or tyrosine kinases. The D-retro-inverso design provides protease resistance while maintaining binding specificity, though at a higher molecular weight than small-molecule alternatives. FOXO4-DRI must be stored lyophilized at -20°C and protected from light and moisture. Reconstitute with bacteriostatic water and store at 2-8°C, using within 2-3 weeks. This peptide is studied by aging biologists, senescence researchers, geroscientists, and nephrology and dermatology researchers investigating senolytic interventions for age-related tissue deterioration.

FOX-04 Research Applications

In published and preclinical research, FOX-04 has been studied across the following areas:

Senescent cell clearance studies
Cardiovascular and renal function
Insulin signaling and stress resilience
Neurological health research

FOX-04 in Research: Study Context

Published preclinical literature characterizes FOXO4-DRI as a peptide that competitively disrupts the FOXO4-p53 interaction, releasing p53 to trigger p53-dependent apoptosis selectively in senescent cells while sparing proliferating cells. In the foundational mouse work (Baar et al., Cell 2017), the peptide reduced markers of senescence and improved fur density, renal function, and treadmill fitness in naturally aged and fast-aging (XpdTTD/TTD) mice; a later report (Tripathi et al., eBioMedicine 2021) further refined the FOXO4-p53-disrupting design. This compound is for laboratory research use only and is NOT FDA-approved; evidence is preclinical (rodent and in vitro) and there is no established human. For laboratory handling, the lyophilized powder is reconstituted with bacteriostatic water to a defined concentration (e.g., 10 mg in 1 mL = 10 mg/mL); investigators should reference the primary literature and document the lot-specific Certificate of Analysis (COA).

How FOX-04 Compares

Researchers frequently evaluate FOX-04 alongside related compounds:

FOX-04 vs Epithalon — Both are studied in an aging-research context, but the mechanisms differ entirely: FOXO4-DRI is investigated as a senolytic that disrupts the FOXO4-p53 interaction to clear senescent cells, whereas Epithalon is studied as a short peptide linked to telomerase/telomere biology rather than senescent-cell apoptosis.

FOX-04 — Frequently Asked Questions

What molecular interaction does FOXO4-DRI target in research models?

It is designed to interfere with the FOXO4-p53 protein-protein interaction. In senescent cells, FOXO4 helps retain p53 in the nucleus and restrains p53-driven apoptosis; in published in vitro and rodent studies the peptide competes for this interaction, promoting p53 nuclear exclusion and p53-dependent apoptosis preferentially in senescent cells. This is a mechanistic research observation, not a validated therapeutic effect.

Why is the D-retro-inverso (DRI) design used?

The D-retro-inverso configuration uses D-amino acids in a reversed sequence to approximate the side-chain topology of the native L-peptide while resisting proteolytic degradation. Researchers use this design to extend stability in experimental systems; it does not imply any approved or characterized clinical pharmacokinetics.

What is the state of the evidence for FOXO4-DRI?

The evidence is early-stage and preclinical, centered on in vitro senescent-cell assays and mouse models (notably Baar et al., Cell 2017). There are no controlled human efficacy or safety data, it is not FDA-approved, and it is intended strictly for laboratory research use. cellular-aging or therapeutic outcomes in humans have not been established.

How is FOXO4-DRI prepared for laboratory use?

Lyophilized peptide is reconstituted with bacteriostatic water to a defined concentration (for a 10 mg vial, 1 mL yields 10 mg/mL), adding diluent slowly down the vial wall without agitation. Store reconstituted solution refrigerated and protected from light, and verify identity/purity against the lot-specific COA before any in vitro work. No human concentration is defined.

Is FOX-04 legal to buy for research?

FOX-04 is sold in the United States as a research chemical for laboratory and in-vitro use only. It is not approved by the FDA for human use and is not sold for human consumption. Researchers are responsible for compliance with all applicable federal, state, and institutional regulations.

Does FOX-04 come with a Certificate of Analysis?

Yes. Every batch of FOX-04 from Elyte Peptides ships with a third-party Certificate of Analysis (COA) documenting identity and HPLC purity (≥98%), so research results can be traced to a verified lot.

What is FOXO4-DRI (Proxofim) and how does it work?

FOXO4-DRI is a D-retro-inverso peptide designed to disrupt the interaction between FOXO4 transcription factor and p53 tumor suppressor protein in senescent cells. In normal senescent cells, FOXO4 binds p53 in the nucleus, preventing p53 from triggering apoptosis. FOXO4-DRI competes with endogenous FOXO4 for p53 binding, releasing p53 to induce selective apoptosis of senescent cells while sparing healthy cells — functioning as a targeted senolytic agent.

What research has been done on FOXO4-DRI?

Landmark research published in Cell (2017) by Baar et al. at Erasmus University Medical Center demonstrated that FOXO4-DRI selectively induced apoptosis in senescent cells both in vitro and in naturally aged mice. Treated mice showed restored fur density, kidney function, and fitness levels. The study showed that FOXO4-DRI's D-retro-inverso structure provided protease resistance while maintaining bioactivity — a key advance in senolytic peptide design.

How does FOXO4-DRI compare to small-molecule senolytics like Dasatinib + Quercetin?

The Dasatinib + Quercetin (D+Q) combination targets senescent cells through kinase inhibition and Bcl-2 family modulation. FOXO4-DRI uses a fundamentally different mechanism — disrupting the specific FOXO4-p53 protein-protein interaction that maintains senescent cell survival. D+Q is orally bioavailable and has more extensive in-vivo data, while FOXO4-DRI offers potentially greater selectivity due to its targeted mechanism. Both represent important tools in senescence research.

Research References

All research guides